Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data.

Big data Conservative management Outcomes PIONEER Prostate cancer Survival

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
04 Jul 2023
Historique:
received: 26 12 2022
revised: 18 05 2023
accepted: 19 06 2023
medline: 7 7 2023
pubmed: 7 7 2023
entrez: 6 7 2023
Statut: aheadofprint

Résumé

Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed. PIONEER, funded by the European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through the application of big data analytics. To describe the clinical characteristics and long-term outcomes of PCa patients on conservative management by using an international large network of real-world data. From an initial cohort of >100 000 000 adult individuals included in eight databases evaluated during a virtual study-a-thon hosted by PIONEER, we identified newly diagnosed PCa cases (n = 527 311). Among those, we selected patients who did not receive curative or palliative treatment within 6 mo from diagnosis (n = 123 146). Patient and disease characteristics were reported. The number of patients who experienced the main study outcomes was quantified for each stratum and the overall cohort. Kaplan-Meier analyses were used to estimate the distribution of time to event data. The most common comorbidities were hypertension (35-73%), obesity (9.2-54%), and type 2 diabetes (11-28%). The rate of PCa-related symptomatic progression ranged between 2.6% and 6.2%. Hospitalization (12-25%) and emergency department visits (10-14%) were common events during the 1st year of follow-up. The probability of being free from both palliative and curative treatments decreased during follow-up. Limitations include a lack of information on patients and disease characteristics and on treatment intent. Our results allow us to better understand the current landscape of patients with PCa managed with conservative treatment. PIONEER offers a unique opportunity to characterize the baseline features and outcomes of PCa patients managed conservatively using real-world data. Up to 25% of men with prostate cancer (PCa) managed conservatively experienced hospitalization and emergency department visits within the 1st year after diagnosis; 6% experienced PCa-related symptoms. The probability of receiving therapies for PCa decreased according to time elapsed after the diagnosis.

Sections du résumé

BACKGROUND BACKGROUND
Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed. PIONEER, funded by the European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through the application of big data analytics.
OBJECTIVE OBJECTIVE
To describe the clinical characteristics and long-term outcomes of PCa patients on conservative management by using an international large network of real-world data.
DESIGN, SETTING, AND PARTICIPANTS METHODS
From an initial cohort of >100 000 000 adult individuals included in eight databases evaluated during a virtual study-a-thon hosted by PIONEER, we identified newly diagnosed PCa cases (n = 527 311). Among those, we selected patients who did not receive curative or palliative treatment within 6 mo from diagnosis (n = 123 146).
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
Patient and disease characteristics were reported. The number of patients who experienced the main study outcomes was quantified for each stratum and the overall cohort. Kaplan-Meier analyses were used to estimate the distribution of time to event data.
RESULTS AND LIMITATIONS CONCLUSIONS
The most common comorbidities were hypertension (35-73%), obesity (9.2-54%), and type 2 diabetes (11-28%). The rate of PCa-related symptomatic progression ranged between 2.6% and 6.2%. Hospitalization (12-25%) and emergency department visits (10-14%) were common events during the 1st year of follow-up. The probability of being free from both palliative and curative treatments decreased during follow-up. Limitations include a lack of information on patients and disease characteristics and on treatment intent.
CONCLUSIONS CONCLUSIONS
Our results allow us to better understand the current landscape of patients with PCa managed with conservative treatment. PIONEER offers a unique opportunity to characterize the baseline features and outcomes of PCa patients managed conservatively using real-world data.
PATIENT SUMMARY RESULTS
Up to 25% of men with prostate cancer (PCa) managed conservatively experienced hospitalization and emergency department visits within the 1st year after diagnosis; 6% experienced PCa-related symptoms. The probability of receiving therapies for PCa decreased according to time elapsed after the diagnosis.

Identifiants

pubmed: 37414703
pii: S0302-2838(23)02944-5
doi: 10.1016/j.eururo.2023.06.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Giorgio Gandaglia (G)

Guidelines Office, European Association of Urology, Arnhem, The Netherlands; Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy. Electronic address: Gandaglia.giorgio@hsr.it.

Francesco Pellegrino (F)

Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.

Asieh Golozar (A)

Odysseus Data Services, New York, NY, USA; OHDSI Center, Northeastern University, Boston, MA, USA.

Bertrand De Meulder (B)

Association EISBM, Vourles, France.

Thomas Abbott (T)

Astellas Pharma, Inc., Northbrook, IL, USA.

Ariel Achtman (A)

The Movember Foundation, Melbourne, Australia.

Muhammad Imran Omar (M)

Guidelines Office, European Association of Urology, Arnhem, The Netherlands; Academic Urology Unit, University of Aberdeen, Scotland, UK.

Thamir Alshammari (T)

Riyadh Elm University, Riyadh, Saudi Arabia.

Carlos Areia (C)

University of Oxford, Oxford, UK.

Alex Asiimwe (A)

Bayer AG, Berlin, Germany.

Katharina Beyer (K)

Translational Oncology and Urology Research, King's College London, London, UK.

Anders Bjartell (A)

Department of Translational Medicine, Lund University, Lund, Sweden.

Riccardo Campi (R)

Guidelines Office, European Association of Urology, Arnhem, The Netherlands; Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Philip Cornford (P)

Liverpool University Hospitals, Liverpool, UK.

Thomas Falconer (T)

Department of Biomedical Informatics, Columbia University, New York, NY, USA.

Qi Feng (Q)

Astellas Pharma, Inc., Northbrook, IL, USA.

Mengchun Gong (M)

Nanfang Hospital, Southern Medical University, Guangzhou, China; DHC Technologies, Beijing, China.

Ronald Herrera (R)

Bayer AG, Berlin, Germany.

Nigel Hughes (N)

Epidemiology, Janssen R&D, Belgium.

Tim Hulsen (T)

Philips Research, Department of Hospital Services & Informatics, Eindhoven, The Netherlands.

Adam Kinnaird (A)

University of Alberta, Edmonton, Canada.

Lana Y H Lai (LYH)

University of Manchester, Manchester, UK.

Gianluca Maresca (G)

Department of Urology, NHS Grampian, Scotland, UK.

Nicolas Mottet (N)

Guidelines Office, European Association of Urology, Arnhem, The Netherlands.

Marek Oja (M)

Institute of Computer Science, University of Tartu, Tartu, Estonia; STACC, Tartu, Estonia.

Peter Prinsen (P)

Netherlands Comprehensive Cancer Organization, Eindhoven, The Netherlands.

Christian Reich (C)

IQVIA, London, UK.

Sebastiaan Remmers (S)

Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands.

Monique J Roobol (MJ)

Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands.

Vasileios Sakalis (V)

Department of Urology, General Hospital of Thessaloniki Agios Pavlos, Thessaloniki, Greece.

Sarah Seager (S)

RWS, IQVIA, Durham, NC, USA.

Emma J Smith (EJ)

Guidelines Office, European Association of Urology, Arnhem, The Netherlands.

Robert Snijder (R)

Astellas Pharma, Inc., Northbrook, IL, USA.

Carl Steinbeisser (C)

Bayer AG, Berlin, Germany.

Nicolas H Thurin (NH)

INSERM CIC-P 1401, Bordeaux PharmacoEpi, Université de Bordeaux, Bordeaux, France.

Ayman Hijazy (A)

Association EISBM, Vourles, France.

Kees van Bochove (K)

The Hyve, Utrecht, The Netherlands.

Roderick C N Van den Bergh (RCN)

St Antonius Hospital, Utrecht, The Netherlands.

Mieke Van Hemelrijck (M)

Translational Oncology and Urology Research, King's College London, London, UK.

Peter-Paul Willemse (PP)

Guidelines Office, European Association of Urology, Arnhem, The Netherlands; Department of Urology, Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.

Andrew E Williams (AE)

The Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, Boston, MA, USA.

Nazanin Zounemat Kermani (N)

Department of Computing, Data Science Institute, Imperial College London, London, England.

Susan Evans-Axelsson (S)

Bayer AG, Berlin, Germany.

Alberto Briganti (A)

Guidelines Office, European Association of Urology, Arnhem, The Netherlands; Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.

James N'Dow (J)

Guidelines Office, European Association of Urology, Arnhem, The Netherlands; Academic Urology Unit, University of Aberdeen, Scotland, UK.

Classifications MeSH